CLGN — Collplant Biotechnologies Balance Sheet
0.000.00%
Last trade - 00:00- $67.47m
- $40.79m
- $10.96m
- 53
- 22
- 76
- 49
Annual balance sheet for Collplant Biotechnologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 3.79 | 3.33 | 43.3 | 29.7 | 26.7 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.349 | 1.07 | 0.694 | 0.552 | 0.393 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5.04 | 5.68 | 45.1 | 31.7 | 28 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5.54 | 4.9 | 5.68 | 5.68 | 5.86 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 10.8 | 10.8 | 51.2 | 37.8 | 34.1 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.46 | 3.39 | 3.01 | 3.1 | 3.25 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.66 | 6.36 | 6.1 | 5.49 | 5.79 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 4.09 | 4.48 | 45.1 | 32.3 | 28.3 |
| Total Liabilities & Shareholders' Equity | 10.8 | 10.8 | 51.2 | 37.8 | 34.1 |
| Total Common Shares Outstanding |